195 related articles for article (PubMed ID: 10590283)
1. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. The Swiss HIV Cohort Study.
Sendi PP; Craig BA; Meier G; Pfluger D; Gafni A; Opravil M; Battegay M; Bucher HC
J Antimicrob Chemother; 1999 Dec; 44(6):811-7. PubMed ID: 10590283
[TBL] [Abstract][Full Text] [Related]
2. Preventing Mycobacterium avium complex in patients who are using protease inhibitors: a cost-effectiveness analysis.
Bayoumi AM; Redelmeier DA
AIDS; 1998 Aug; 12(12):1503-12. PubMed ID: 9727572
[TBL] [Abstract][Full Text] [Related]
3. Azithromycin prophylaxis for Mycobacterium avium complex during the era of highly active antiretroviral therapy: evaluation of a provincial program.
Phillips P; Chan K; Hogg R; Bessuille E; Black W; Talbot J; O'Shaughnessy M; Montaner J
Clin Infect Dis; 2002 Feb; 34(3):371-8. PubMed ID: 11774085
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of preventing AIDS-related opportunistic infections.
Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of prophylaxis for Mycobacterium avium complex in AIDS.
Scharfstein JA; Paltiel AD; Weinstein MC; Seage GR; Losina E; Craven DE; Freedberg KA
Int J Technol Assess Health Care; 1999; 15(3):531-47. PubMed ID: 10874380
[TBL] [Abstract][Full Text] [Related]
7. Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS.
El-Sadr WM; Burman WJ; Grant LB; Matts JP; Hafner R; Crane L; Zeh D; Gallagher B; Mannheimer SB; Martinez A; Gordin F
N Engl J Med; 2000 Apr; 342(15):1085-92. PubMed ID: 10766581
[TBL] [Abstract][Full Text] [Related]
8. Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.
Freedberg KA; Cohen CJ; Barber TW
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(4):275-82. PubMed ID: 9292586
[TBL] [Abstract][Full Text] [Related]
9. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy.
Karakousis PC; Moore RD; Chaisson RE
Lancet Infect Dis; 2004 Sep; 4(9):557-65. PubMed ID: 15336223
[TBL] [Abstract][Full Text] [Related]
10. Disseminated mycobacterium avium-intracellulare complex (MAC) infection in the era of effective antiretroviral therapy: is prophylaxis still indicated?
Lange CG; Woolley IJ; Brodt RH
Drugs; 2004; 64(7):679-92. PubMed ID: 15025543
[TBL] [Abstract][Full Text] [Related]
11. Presence of macrolide resistance in respiratory flora of HIV-Infected patients receiving either clarithromycin or azithromycin for Mycobacterium avium complex prophylaxis.
Aberg JA; Wong MK; Flamm R; Notario GF; Jacobson MA
HIV Clin Trials; 2001; 2(6):453-9. PubMed ID: 11742432
[TBL] [Abstract][Full Text] [Related]
12. Prevention strategies for Mycobacterium avium-intracellulare complex (MAC) infection. A review of recent studies in patients with AIDS.
Cohn DL
Drugs; 1997; 54 Suppl 2():8-15; discussion 28-9. PubMed ID: 9358195
[TBL] [Abstract][Full Text] [Related]
13. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART?
Yangco BG; Buchacz K; Baker R; Palella FJ; Armon C; Brooks JT;
AIDS Patient Care STDS; 2014 Jun; 28(6):280-3. PubMed ID: 24833016
[TBL] [Abstract][Full Text] [Related]
14. Incidence of disseminated Mycobacterium avium-complex infection in HIV patients receiving antiretroviral therapy with use of Mycobacterium avium-complex prophylaxis.
Jung Y; Song KH; Choe PG; Park WB; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Oh MD
Int J STD AIDS; 2017 Dec; 28(14):1426-1432. PubMed ID: 28592210
[TBL] [Abstract][Full Text] [Related]
15. Model for simulation of HIV/AIDS and cost-effectiveness of preventing non-tuberculous mycobacterial (MAC)-disease.
Hoffmann T; Brunner H
Eur J Health Econ; 2004 Jun; 5(2):129-35. PubMed ID: 15452749
[TBL] [Abstract][Full Text] [Related]
16. Azithromycin in the prophylaxis of opportunistic infections in AIDS.
McCutchan JA
Int J STD AIDS; 1996; 7 Suppl 1():34-7. PubMed ID: 8652726
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.
Havlir DV; Dubé MP; Sattler FR; Forthal DN; Kemper CA; Dunne MW; Parenti DM; Lavelle JP; White AC; Witt MD; Bozzette SA; McCutchan JA
N Engl J Med; 1996 Aug; 335(6):392-8. PubMed ID: 8676932
[TBL] [Abstract][Full Text] [Related]
18. Interventions for the prevention of mycobacterium avium complex in adults and children with HIV.
Uthman MM; Uthman OA; Yahaya I
Cochrane Database Syst Rev; 2013 Apr; (4):CD007191. PubMed ID: 23633339
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.
Sendi PP; Bucher HC; Harr T; Craig BA; Schwietert M; Pfluger D; Gafni A; Battegay M
AIDS; 1999 Jun; 13(9):1115-22. PubMed ID: 10397543
[TBL] [Abstract][Full Text] [Related]
20. Rationale for the prevention of disseminated Mycobacterium avium-intracellulare complex disease.
Dautzenberg B
Drugs; 1997; 54 Suppl 2():1-7; discussion 28-9. PubMed ID: 9358194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
